Perinatal Center for Maternity and Neonate, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
Perinatal Center for Maternity and Neonate, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
BMJ Open Diabetes Res Care. 2023 Jun;11(3). doi: 10.1136/bmjdrc-2022-003230.
To verify the effectiveness of intervention in early pregnancy for women with early-onset gestational diabetes mellitus (GDM).
This study included women with a singleton pregnancy who were diagnosed with early-onset GDM by 20 weeks of gestation according to the International Association of Diabetes and Pregnancy Study Group (IADPSG) threshold. We retrospectively evaluated the pregnancy outcomes in pregnant women with early-onset GDM. In the treatment from early pregnancy group (n=286), patients were diagnosed with early-onset GDM at the Yokohama City University Medical Center (YCU-MC) in 2015-2017 and were treated for GDM from early pregnancy. Concerning the treatment from mid-pregnancy group (n=248), participants were diagnosed with early-onset GDM at five sites, including the YCU-MC in 2018-2019, and were followed up without treatment until the second 75 g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. Treatment for GDM was given only if the GDM pattern was still present in the second OGTT.
There were no significant differences in maternal backgrounds, including GDM risk factors and gestational weight gain, between the groups. Among the treatment from mid-pregnancy group, the false-positive early GDM was 124/248 (50%). Regarding pregnancy outcome, the rate of large for gestational age (LGA) was 8.8% in the treatment from early pregnancy group and 10% in the treatment from mid-pregnancy group, with no significant difference, whereas small for gestational age (SGA) was significantly higher in the treatment from early pregnancy group (9.4%) than in the treatment from mid-pregnancy group (4.8%) (p=0.046). There were no significant differences in maternal adverse events and neonatal outcomes between the groups. In a subanalysis limited to body mass index >25 kg/m, LGA was significantly lower in the treatment from early pregnancy group than in the treatment from mid-pregnancy group.
The strategy for diagnosing GDM by IADPSG thresholds in early pregnancy and providing treatment to all patients from early pregnancy did not improve the pregnancy outcomes, but rather increased the SGA rate.
为了验证对早发型妊娠期糖尿病(GDM)患者进行早期妊娠干预的效果。
本研究纳入了单胎妊娠的女性,这些女性根据国际妊娠糖尿病研究协会(IADPSG)标准在 20 周前被诊断为早发型 GDM。我们回顾性评估了早发型 GDM 孕妇的妊娠结局。在早孕期治疗组(n=286)中,患者于 2015-2017 年在横滨市立大学医学中心(YCU-MC)被诊断为早发型 GDM,并从早孕期开始接受 GDM 治疗。关于中孕期治疗组(n=248),参与者于 2018-2019 年在 YCU-MC 等五个地点被诊断为早发型 GDM,未接受治疗,直至 24-28 周的第二次 75g 口服葡萄糖耐量试验(OGTT)。仅在第二次 OGTT 中仍存在 GDM 模式时才给予 GDM 治疗。
两组之间的母体背景,包括 GDM 危险因素和妊娠体重增加,没有显著差异。在中孕期治疗组中,假阳性早发型 GDM 为 124/248(50%)。关于妊娠结局,早孕期治疗组的巨大儿(LGA)发生率为 8.8%,中孕期治疗组为 10%,差异无统计学意义,而早孕期治疗组的小于胎龄儿(SGA)发生率明显高于中孕期治疗组(9.4%比 4.8%)(p=0.046)。两组之间的母体不良事件和新生儿结局无显著差异。在体重指数(BMI)>25kg/m²的亚分析中,早孕期治疗组的 LGA 明显低于中孕期治疗组。
通过 IADPSG 标准在早孕期诊断 GDM 并对所有患者从早孕期开始治疗的策略并没有改善妊娠结局,反而增加了 SGA 的发生率。